Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- ASCO Immunotherapy Roundup - 4: Merck KGaA Trailing Rivals with ADCC-Inducing Avelumab
July 30, 2015
- Takecab Maintains Top Position for 6th Month Running in HP Market in June: Anterio Ranking
July 30, 2015
- Lenvima Receives Breakthrough Therapy Designation from US FDA
July 30, 2015
- Rebetol Approved for Combination Use with Sovaldi for Genotype 2 Chronic Hepatitis C Virus Infection: MSD
July 30, 2015
- Teijin Pharma Files Feburic for Hyperuricemia in Patients Undergoing Chemotherapy in Japan
July 30, 2015
- Delving into Securities Filings - 2: Drug Maker Employees Decrease 0.9% in 5 Years
July 30, 2015
- New AbbVie Japan Chief Says Generics Making Room for Innovation
July 29, 2015
- Kyowa Kirin Kicks Off Japan PIII Study on Benralizumab for COPD
July 29, 2015
- EMA Accepts Applications for Opdivo for Non-Squamous NSCLC and in Combination with Yervoy for Advanced Melanoma: BMS
July 29, 2015
- Chugai’s Sales Reps to Provide ADR Information on the Spot from Mid-2016
July 29, 2015
- MSD Applies for 9-Valent HPV Vaccine
July 29, 2015
- Ixazomib Granted Accelerated Assessment in EU: Takeda
July 29, 2015
- Takeda, DNDi Partner for Development of Visceral Leishmaniasis Treatment
July 29, 2015
- Carfilzomib Approved for Combination Use in US: Ono
July 29, 2015
- Delving into Securities Filings - 1: Average Salary of 25 Makers Up 4.9% in 5 Years, Generic Players Close in on Top-Tier Firms
July 29, 2015
- Eisai Files for Regulatory Approval of Perampanel in Japan
July 28, 2015
- Japan Drug Makers Should Consider Mergers, Other Deals to Survive: Chugai Chief
July 27, 2015
- Toho to Narrow Down Recommended Drug Makers, Will Need to Devise Specific Marketing Policy for Generics: Pres. Edahiro
July 27, 2015
- Fujifilm, Kyowa Kirin JV to Develop Avastin Biosimilar with AZ
July 27, 2015
- Kyowa Kirin Ups Earnings Outlook on Nesp, G-Lasta
July 27, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…